Frequently asked questions:
The COVID-19 pandemic affected the non-invasive prenatal testing (NIPT) market due to the suspension of non-invasive prenatal screening (NIPS) services to prevent the COVID-19 virus’s spread. One of the factors inhibiting hospitals and diagnostic centers from providing non-invasive prenatal screening (NIPS) services was the immense burden on hospitals to provide services to COVID-19 patients.
North America accounted for the most heightened share in the global non-invasive prenatal testing market.
Prenatal testing witnesses a shift towards noninvasive tests, and the growing prevalence of chromosomal abnormalities to augment demand for NIPT industry drive the non-invasive prenatal testing market.
The high and average risks segment had a major share in the global market in 2022.
The 13-24 weeks gestation period segment had a major share in the global market.